Donald C Vinh

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7826080/publications.pdf

Version: 2024-02-01

141 papers	12,842 citations	66234 42 h-index	26548 107 g-index
149 all docs	149 docs citations	149 times ranked	20317 citing authors

#	Article	IF	Citations
1	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science, 2020, 370, .	6.0	1,983
2	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science, 2020, 370, .	6.0	1,749
3	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet, The, 2020, 395, 1907-1918.	6.3	1,395
4	Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infectious Diseases, The, 2003, 3, 148-155.	4.6	710
5	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infectious Diseases, The, 2021, 21, e149-e162.	4.6	586
6	Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood, 2011, 118, 2653-2655.	0.6	572
7	Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Science Immunology, 2021, 6, .	5.6	357
8	Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood, 2010, 115, 1519-1529.	0.6	299
9	X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Science Immunology, 2021, 6, .	5.6	267
10	Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Annals of Oncology, 2021, 32, 787-800.	0.6	240
11	Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. Journal of Allergy and Clinical Immunology, 2013, 131, 1624-1634.e17.	1.5	222
12	Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature, 2022, 603, 587-598.	13.7	216
13	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). Journal of Hematology and Oncology, 2021, 14, 168.	6.9	189
14	SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin. Nature, 2017, 544, 493-497.	13.7	188
15	A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection. Cell, 2020, 181, 1194-1199.	13.5	185
16	Linezolid: a review of safety and tolerability. Journal of Infection, 2009, 59, S59-S74.	1.7	170
17	The Fungal Exopolysaccharide Galactosaminogalactan Mediates Virulence by Enhancing Resistance to Neutrophil Extracellular Traps. PLoS Pathogens, 2015, 11, e1005187.	2.1	167
18	NADPH Oxidase Limits Innate Immune Responses in the Lungs in Mice. PLoS ONE, 2010, 5, e9631.	1.1	161

#	Article	IF	Citations
19	CARD9 Deficiency and Spontaneous Central Nervous System Candidiasis: Complete Clinical Remission With GM-CSF Therapy. Clinical Infectious Diseases, 2014, 59, 81-84.	2.9	153
20	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2200413119.	3.3	110
21	Refractory Disseminated Coccidioidomycosis and Mycobacteriosis in Interferonâ€Î³ Receptor 1 Deficiency. Clinical Infectious Diseases, 2009, 49, e62-e65.	2.9	109
22	Device-Related Infections: A Review. Journal of Long-Term Effects of Medical Implants, 2005, 15, 467-488.	0.2	108
23	Invasive Aspergillosis Due toNeosartorya udagawae. Clinical Infectious Diseases, 2009, 49, 102-111.	2.9	103
24	Inborn errors of immunity underlying fungal diseases in otherwise healthy individuals. Current Opinion in Microbiology, 2017, 40, 46-57.	2.3	101
25	Rapidly progressive soft tissue infections. Lancet Infectious Diseases, The, 2005, 5, 501-513.	4.6	97
26	Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications. Haematologica, 2011, 96, 1221-1225.	1.7	97
27	Impaired RASGRF1/ERKâ€“mediated GM-CSF response characterizes CARD9 deficiency in French-Canadians. Journal of Allergy and Clinical Immunology, 2016, 137, 1178-1188.e7.	1.5	92
28	Invasive fungal disease in autosomal-dominant hyper-IgE syndrome. Journal of Allergy and Clinical Immunology, 2010, 125, 1389-1390.	1.5	91
29	Interleukin-12 Receptor Â1 Deficiency Predisposing to Disseminated Coccidioidomycosis. Clinical Infectious Diseases, 2011, 52, e99-e102.	2.9	87
30	Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies. Journal of Cutaneous Medicine and Surgery, 2019, 23, 50-74.	0.6	87
31	Insights into human antifungal immunity from primary immunodeficiencies. Lancet Infectious Diseases, The, 2011, 11, 780-792.	4.6	72
32	Studying severe long COVID to understand post-infectious disorders beyond COVID-19. Nature Medicine, 2022, 28, 879-882.	15.2	72
33	Neosartorya udagawae (Aspergillus udagawae), an Emerging Agent of Aspergillosis: How Different Is It from Aspergillus fumigatus ?. Journal of Clinical Microbiology, 2010, 48, 220-228.	1.8	68
34	High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study. European Journal of Cancer, 2020, 139, 181-187.	1.3	65
35	RIPK3 interacts with MAVS to regulate type I IFN-mediated immunity to Influenza A virus infection. PLoS Pathogens, 2017, 13, e1006326.	2.1	60
36	Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia. Journal of Experimental Medicine, 2022, 219, .	4.2	59

#	Article	IF	Citations
37	Canadian Clinical Practice Guidelines for Invasive Candidiasis in Adults. Canadian Journal of Infectious Diseases and Medical Microbiology, 2010, 21, e122-e150.	0.7	56
38	Chronic Invasive Aspergillosis caused byAspergillus viridinutans. Emerging Infectious Diseases, 2009, 15, 1292-1294.	2.0	54
39	Native-valve bacterial endocarditis caused by Lactococcus garvieae. Diagnostic Microbiology and Infectious Disease, 2006, 56, 91-94.	0.8	53
40	Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations. Journal of Allergy and Clinical Immunology, 2020, 146, 479-491.e5.	1.5	52
41	BCG vaccination provides protection against IAV but not SARS-CoV-2. Cell Reports, 2022, 38, 110502.	2.9	51
42	Breast implant infection with Mycobacterium fortuitum group: Report of case and review. Journal of Infection, 2006, 52, e63-e67.	1.7	46
43	Mucormycosis in chronic granulomatous disease: Association with iatrogenic immunosuppression. Journal of Allergy and Clinical Immunology, 2009, 123, 1411-1413.	1.5	42
44	Cell-free DNA tissues of origin by methylation profiling reveals significant cell, tissue, and organ-specific injury related to COVID-19 severity. Med, 2021, 2, 411-422.e5.	2.2	41
45	A global effort to dissect the human genetic basis of resistance to SARS-CoV-2 infection. Nature Immunology, 2022, 23, 159-164.	7.0	41
46	Loss of human ICOSL results in combined immunodeficiency. Journal of Experimental Medicine, 2018, 215, 3151-3164.	4.2	40
47	Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-Î². Journal of Clinical Immunology, 2021, 41, 1425-1442.	2.0	39
48	Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. Science Immunology, 2023, 8, .	5.6	35
49	Yeast Infections â€" Human Genetics on the Rise. New England Journal of Medicine, 2009, 361, 1798-1801.	13.9	33
50	Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. JAMA Network Open, 2021, 4, e2134330.	2.8	32
51	Leukotriene B4â€"type I interferon axis regulates macrophage-mediated disease tolerance to influenza infection. Nature Microbiology, 2019, 4, 1389-1400.	5.9	31
52	Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn). Journal of Antimicrobial Chemotherapy, 2019, 74, 3315-3327.	1.3	30
53	The Biobanque quÃ©bÃ©coise de la COVID-19 (BQC19)â€"A cohort to prospectively study the clinical and biological determinants of COVID-19 clinical trajectories. PLoS ONE, 2021, 16, e0245031.	1.1	30
54	A Canadian Perspective on the Use of Immunoglobulin Therapy to Reduce Infectious Complications in Chronic Lymphocytic Leukemia. Current Oncology, 2016, 23, 42-51.	0.9	28

#	Article	IF	Citations
55	Neutropenia in kidney and liver transplant recipients: Risk factors and outcomes. Clinical Transplantation, 2017, 31, e13058.	0.8	28
56	Longitudinal Plasma Proteomics Analysis Reveals Novel Candidate Biomarkers in Acute COVID-19. Journal of Proteome Research, 2022, 21, 975-992.	1.8	27
57	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. Cancer Cell, 2020, 38, 761-766.	7.7	26
58	Evaluation of a Commercial Direct Fluorescent-Antibody Assay for Human Metapneumovirus in Respiratory Specimens. Journal of Clinical Microbiology, 2008, 46, 1840-1841.	1.8	25
59	GM-CSF therapy in human caspase recruitment domainâ€“containing protein 9 deficiency. Journal of Allergy and Clinical Immunology, 2018, 142, 1334-1338.e5.	1.5	24
60	Novel CARD9 mutation in a patient with chronic invasive dermatophyte infection (tinea profunda). Journal of Cutaneous Pathology, 2020, 47, 166-170.	0.7	24
61	Primary immunodeficiency associated with chromosomal aberration â€“ an ESID survey. Orphanet Journal of Rare Diseases, 2016, 11, 110.	1.2	23
62	â€˜Bobo-Newton Syndromeâ€™: An Unwanted Gift from Manâ€™s Best Friend. Canadian Journal of Infectious Diseases and Medical Microbiology, 2013, 24, 209-214.	0.7	22
63	Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary. Journal of Rheumatology, 2019, 46, 751-754.	1.0	22
64	First Report of Isolation and Characterization of Aurantimonas altamirensis from Clinical Samples. Journal of Clinical Microbiology, 2008, 46, 2435-2437.	1.8	21
65	Invasive Saccharomyces cerevisiae in a liver transplant patient: case report and review of infection in transplant recipients. Transplant Infectious Disease, 2015, 17, 435-441.	0.7	21
66	CD109 Restrains Activation of Cutaneous IL-17-Producing Î³Î´ T Cells by Commensal Microbiota. Cell Reports, 2019, 29, 391-405.e5.	2.9	21
67	Nasal Nitric Oxide in Primary Immunodeficiency and Primary Ciliary Dyskinesia: Helping to Distinguish Between Clinically Similar Diseases. Journal of Clinical Immunology, 2019, 39, 216-224.	2.0	21
68	From Your Nose to Your Toes: A Review of Severe Acute Respiratory Syndrome Coronavirus 2 Pandemicâ€'Associated Pernio. Journal of Investigative Dermatology, 2021, 141, 2791-2796.	0.3	21
69	Respiratory viral infections in otherwise healthy humans with inherited IRF7 deficiency. Journal of Experimental Medicine, 2022, 219, .	4.2	21
70	Vibrio vulnificusSepticemia after HandlingTilapiaSpecies Fish: A Canadian Case Report and Review. Canadian Journal of Infectious Diseases and Medical Microbiology, 2006, 17, 129-132.	0.7	20
71	Crohnâ€™s as an immune deficiency: from apparent paradox to evolving paradigm. Expert Review of Clinical Immunology, 2013, 9, 17-30.	1.3	20
72	Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScopeâ€“‡â€”Global Registry for Emerging Fungal Infections. Journal of Infection, 2020, 81, 802-815.	1.7	20

#	Article	IF	Citations
73	Candida dubliniensis bloodstream infection: a fatal case in a lung transplant recipient. Transplant Infectious Disease, 2005, 7, 146-149.	0.7	18
74	Novel biâ€allelic splice mutations in <scp>CARD</scp>9 causing adultâ€onset Candida endophthalmitis. Mycoses, 2018, 61, 61-65.	1.8	18
75	Famciclovir: a focus on efficacy and safety. Expert Opinion on Drug Safety, 2010, 9, 643-658.	1.0	17
76	Lack of evidence for intergenerational inheritance of immune resistance to infections. Nature Immunology, 2022, 23, 203-207.	7.0	17
77	The man who got too close to his cows. Diagnostic Microbiology and Infectious Disease, 2008, 60, 419-420.	0.8	16
78	Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors. CJC Open, 2021, 3, 965-975.	0.7	15
79	Severe skin and soft tissue infections and associated critical illness. Current Infectious Disease Reports, 2007, 9, 415-421.	1.3	14
80	Morpholino-based correction of hypomorphic ZAP70 mutation in an adult with combined immunodeficiency. Journal of Allergy and Clinical Immunology, 2017, 139, 1688-1692.e10.	1.5	14
81	A systems biology approach identifies candidate drugs to reduce mortality in severely ill patients with COVID-19. Science Advances, 2022, 8, .	4.7	14
82	Famciclovir for the treatment of recurrent genital herpes: a clinical and pharmacological perspective. Expert Opinion on Pharmacotherapy, 2006, 7, 2271-2286.	0.9	12
83	ICOSL in host defense at epithelial barriers: lessons from ICOSLG deficiency. Current Opinion in Immunology, 2021, 72, 21-26.	2.4	12
84	Acute Kidney Injury and Renal Replacement Therapy in COVID-19 Versus Other Respiratory Viruses: A Systematic Review and Meta-Analysis. Canadian Journal of Kidney Health and Disease, 2021, 8, 205435812110521.	0.6	12
85	Legionella jordanis Lower Respiratory Tract Infection: Case Report and Review. Journal of Clinical Microbiology, 2007, 45, 2321-2323.	1.8	11
86	Hantavirus Pulmonary Syndrome: A Concise Clinical Review. Southern Medical Journal, 2009, 102, 620-625.	0.3	11
87	Cytokine immunomodulation for the treatment of infectious diseases: lessons from primary immunodeficiencies. Expert Review of Clinical Immunology, 2014, 10, 1069-1100.	1.3	11
88	Risk factors for severe infections in secondary immunodeficiency: a retrospective US administrative claims study in patients with hematological malignancies. Leukemia and Lymphoma, 2022, 63, 64-73.	0.6	11
89	Coccidioidal Meningitis. Medicine (United States), 2011, 90, 87.	0.4	10
90	Renin-Angiotensin System Pathway Therapeutics Associated With Improved Outcomes in Males Hospitalized With COVID-19*. Critical Care Medicine, 2022, 50, 1306-1317.	0.4	10

#	Article	IF	Citations
91	Infection in breast implants. Lancet Infectious Diseases, The, 2005, 5, 462-463.	4.6	9
92	Prefilled syringes for immunoglobulin G (IgG) replacement therapy: clinical experience from other disease settings. Expert Opinion on Drug Delivery, 2018, 15, 1199-1209.	2.4	8
93	Severe skin and soft tissue infections and associated critical illness. Current Infectious Disease Reports, 2006, 8, 375-383.	1.3	7
94	Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada. Emerging Infectious Diseases, 2019, 25, 838-840.	2.0	7
95	A Toolkit and Framework for Optimal Laboratory Evaluation of Individuals with Suspected Primary Immunodeficiency. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3293-3307.e6.	2.0	7
96	Autoimmune Lymphoproliferative Syndrome and Epstein-Barr Virus-Associated Lymphoma: An Adjunctive Diagnostic Role for Monitoring EBV Viremia?. Case Reports in Immunology, 2013, 2013, 1-5.	0.2	6
97	The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples. Leukemia and Lymphoma, 2018, 59, 2159-2174.	0.6	6
98	The molecular immunology of human susceptibility to fungal diseases: lessons from single gene defects of immunity. Expert Review of Clinical Immunology, 2019, 15, 461-486.	1.3	6
99	Not So Pretty in Pink: Staphylococcus cohnii Masquerading as Methicillin-Resistant Staphylococcus aureus on Chromogenic Media. Journal of Clinical Microbiology, 2006, 44, 4623-4624.	1.8	5
100	A Cluster of Three Cases ofHantavirusPulmonary Syndrome among Canadian Military Personnel. Canadian Journal of Infectious Diseases and Medical Microbiology, 2016, 2016, 1-4.	0.7	5
101	Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapiesâ€"Executive Summary. Journal of the Canadian Association of Gastroenterology, 2019, 2, 149-152.	0.1	5
102	Infections in secondary immunodeficiency patients treated with Privigen^{Â®} or Hizentra^{Â®}: a retrospective US administrative claims study in patients with hematological malignancies. Leukemia and Lymphoma, 2021, 62, 3463-3473.	0.6	5
103	Strains and toxins of Clostridium. Cmaj, 2005, 172, 312-313.	0.9	4
104	Chronic mucocutaneous candidiasis presenting as Candida endophthalmitis. Canadian Journal of Ophthalmology, 2016, 51, e55-e58.	0.4	4
105	GATA2 Deficiency Due to de Novo Complete Monoallelic Deletion in an Adolescent With Myelodysplasia. Journal of Pediatric Hematology/Oncology, 2018, 40, e225-e228.	0.3	4
106	Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: Findings from the Pump-Assisted Administration Cohorts of the HILO Study. Journal of Clinical Immunology, 2021, 41, 458-469.	2.0	4
107	Fecal host biomarkers predicting severity of Clostridioides difficile infection. JCI Insight, 2021, 6, .	2.3	4
108	CrohnÊ¼s Disease and M. paratuberculosis: WhereÊ¼s the Beef?. Inflammatory Bowel Diseases, 2005, 11, 1025-1027.	0.9	3

#	Article	IF	Citations
109	Severe disseminated Nocardia infection associated with ustekinumab treatment for psoriasis. British Journal of Dermatology, 2019, 181, 194-195.	1.4	3
110	Safety and Tolerability of Manual Push Administration of Subcutaneous IgPro20 at High Infusion Rates in Patients with Primary Immunodeficiency: Findings from the Manual Push Administration Cohort of the HILO Study. Journal of Clinical Immunology, 2021, 41, 66-75.	2.0	3
111	miR-181c regulates MCL1 and cell survival in GATA2 deficient cells. Journal of Leukocyte Biology, 2022, 111, 805-816.	1.5	3
112	Organ dysfunction and death in patients admitted to hospital with COVID-19 in pandemic waves 1 to 3 in British Columbia, Ontario and Quebec, Canada: a cohort study. CMAJ Open, 2022, 10, E379-E389.	1.1	3
113	Rapidly progressive soft tissue infections â€“ Authors' reply. Lancet Infectious Diseases, The, 2006, 6, 66-67.	4.6	2
114	Clinical Applications of Induced Sputum. Chest, 2006, 130, 1626-1627.	0.4	2
115	Treatment of Native Valve Endocarditis: General Principles and Therapy for Specific Organisms. , 2006, , 121-183.		2
116	2007 International Congress on Respiratory Viruses. Pediatric Infectious Disease Journal, 2008, 27, S49-S51.	1.1	1
117	Acquired Omenn-Like Syndrome, a Novel Posttransplant Autoaggression Syndrome Reversed by Rapamycin. Vaccine Journal, 2012, 19, 109-112.	3.2	1
118	Risk Factors for Progression of CMV Viremia to CMV Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, S296-S297.	2.0	1
119	Case of Reversible Complete Heart Block. American Journal of Medicine, 2017, 130, e335-e336.	0.6	1
120	Back from the brink of obscurity. ELife, 2018, 7, .	2.8	1
121	The HILO Study: High Volumes and Flow Rates of Subcutaneous IgPro20 Pump-assisted Infusions in Patients with Primary Immunodeficiency. Journal of Allergy and Clinical Immunology, 2020, 145, AB216.	1.5	1
122	Real-World Serologic Responses to Extended-Interval and Heterologous COVID-19 mRNA Vaccination in Frail Elderly - Interim Report from a Prospective Observational Cohort Study. SSRN Electronic Journal, 0, , .	0.4	1
123	Treatment of Endocarditis. , 2016, , 181-280.		1
124	Late-Onset Combined Immunodeficiency with Refractory CMV Disease due to ICOSL Deficiency. Journal of Clinical Immunology, 2021, , 1.	2.0	1
125	An Elderly Woman with a Diffuse Annular Eruption. Clinical Infectious Diseases, 2008, 46, 1581-1581.	2.9	0
126	Clinical and Molecular Epidemiology of Histoplasma capsulatum in Quebec, Canada. Open Forum Infectious Diseases, 2016, 3, .	0.4	0

#	Article	IF	Citations
127	CARD9 Deficiency. , 2017, , 1-22.		0
128	CARD9 Deficiency. , 2018, , 1-22.		0
129	Pre-filled Syringes For Immunoglobulin Therapy: A Pragmatic Review Of Clinical Experience From Other Disease Settings. Journal of Allergy and Clinical Immunology, 2018, 141, AB266.	1.5	0
130	Disseminated Pruritic Macules in a Solid Organ Transplant Recipient. Clinical Infectious Diseases, 2019, 69, 897-899.	2.9	0
131	Feasibility of Subcutaneous IgPro20 Administration via Manual Push at High Flow Rates in Patients with Primary Immunodeficiency: Findings of the HILO Study. Journal of Allergy and Clinical Immunology, 2020, 145, AB217.	1.5	0
132	Safety Profile of High IgPro20 Infusion Parameters in Patients with Primary Immunodeficiency (PID): Results from The Forced Upward Titration HILO Study. Journal of Allergy and Clinical Immunology, 2020, 145, AB32.	1.5	0
133	Treatment of Secondary Immunodeficiencies. , 2021, , .		0
134	MCL-1 and Mir-181c in GATA2 Mutation Associated Monomac and Familial Myelodysplastic Syndrome. Blood, 2012, 120, 3807-3807.	0.6	0
135	Macrophage Classical Activation. , 0, , 301-323.		0
136	Prophylaxis of Endocarditis. , 2016, , 67-90.		0
137	Abstract 2447: The mutational landscape of chemo-refractory Burkitt lymphoma. , 2017, , .		0
138	CARD9 Deficiency. , 2020, , 96-117.		0
139	Abstract S12-01: High mortality among hospital-acquired COVID-19 infection in patients with cancer: An observational cohort study from Quebec and British Columbia. , 2020, , .		0
140	Fever, abdominal pain, serositis, arthralgia, hearing loss, proteinuria, and a family history: Muckle Wells syndrome. Lancet, The, 2021, 398, 2101.	6.3	0
141	Plerixafor on a WHIM - Promise or Fantasy of a New CXCR4 Inhibitor for This Rare, but Important Syndrome?. Skin Therapy Letter, 2022, 27, 1-5.	0.3	0